Drug Trial Radar · NCT00000512
Familial Atherosclerosis Treatment Study
Last checked: Nov 20, 2026Latest source record: Dec 3, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
146
Actual
Start
Jan 1984
Primary completion
Aug 1989
Study completion Aug 1989
Sponsor
- Lead sponsor
- University of WashingtonAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Heart, Lung, and Blood Institute (NHLBI)
- First posted
- Oct 28, 1999
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- Male only, from 18 years, up to 62 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To compare the effects of two intensive lipid-lowering regimens with conventional therapy on coronary atherosclerosis as assessed by arteriography.
Conditions
- Cardiovascular Diseases
- Coronary Arteriosclerosis
- Coronary Disease
- Heart Diseases
- Myocardial Ischemia
Interventions
lovastatinDrug
Lovastatin was begun at a dose of 20 mg twice a day (in the morning and at bedtime). If the LDL cholesterol level did not fall below 3.1 mmol per liter after three months, the dose of lovastatin was increased to 40 mg twice a day.
colestipolDrug
Colestipol was begun at a dose of 5 g three times a day with meals and increased to 10 g three times a day after 10 days, unless side effects delayed the increase. Psyllium hydrophic mucilloid (Metamucil) was provided if dietary bran was insufficient to control constipation.
niacinDrug
Niacin was started at 125 mg twice a day and gradually increased to 500 mg four times a day (with meals and at bedtime) at one month and 1 g four times a day at two months. If the LDL cholesterol level did not fall below 3.1 mmol per liter (120 mg per deciliter) after three months, the dose of niacin was increased to 1.5 g (three tablets) four times a day, but no further.
Placebo for colestipolOther
Placebo for colestipol.
Placebo for lovastatinOther
Placebo for lovastatin
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in the Mean Severity of Proximal StenosisTime frame: Baseline and 2.5 years of therapy.
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.